ImmunoCellular Therapeutics Ltd Stock Price, News & Analysis (NYSEAMERICAN:IMUC)

$0.34 0.01 (3.03 %)
(As of 11/21/2017 03:10 AM ET)
Previous Close$0.33
Today's Range$0.33 - $0.35
52-Week Range$0.25 - $4.27
Volume682,300 shs
Average Volume1.14 million shs
Market Capitalization$5.35 million
P/E RatioN/A
Dividend YieldN/A
Beta1.02

About ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC)

ImmunoCellular Therapeutics Ltd logoImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is developing immune-based therapies for the treatment of cancers. The Company's cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is in phase III testing. In addition, the Company also has a portfolio of other potential therapeutic immunotherapies using a range of approaches to treat cancer. Its other product candidates are ICT-140 and ICT-121. ICT-107 is a dendritic cell (DC) vaccine for the treatment of newly diagnosed glioblastoma multiforme (GBM), a type of brain cancer. ICT-140 is a DC vaccine that targets over seven tumor-associated antigens expressed on ovarian cancer cells. It is developing ICT-121, a dendritic cell (DC)-based vaccine targeting CD133+ CSCs for the treatment of recurrent GBM and other solid tumor cancers, including ovarian, pancreatic and breast cancers.


Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Sector: N/A
  • Symbol: NYSEAMERICAN:IMUC
  • CUSIP: 45253610
  • Web: imuc.com
Profitability:
  • Trailing EPS: ($6.02)
  • Return on Assets: -189.02%
Misc:
  • Outstanding Shares: 15,840,000
 

Frequently Asked Questions for ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC)

What is ImmunoCellular Therapeutics Ltd's stock symbol?

ImmunoCellular Therapeutics Ltd trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IMUC."

How were ImmunoCellular Therapeutics Ltd's earnings last quarter?

ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC) released its earnings results on Monday, August, 22nd. The biotechnology company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. View ImmunoCellular Therapeutics Ltd's Earnings History.

Are investors shorting ImmunoCellular Therapeutics Ltd?

ImmunoCellular Therapeutics Ltd saw a decrease in short interest in the month of October. As of October 31st, there was short interest totalling 1,679,860 shares, a decrease of 0.9% from the October 13th total of 1,694,466 shares. Based on an average trading volume of 2,347,634 shares, the days-to-cover ratio is currently 0.7 days. Approximately 10.6% of the company's stock are short sold.

Who are some of ImmunoCellular Therapeutics Ltd's key competitors?

Who are ImmunoCellular Therapeutics Ltd's key executives?

ImmunoCellular Therapeutics Ltd's management team includes the folowing people:

  • Anthony J. Gringeri Ph.D., President, Chief Executive Officer, Director (Age 62)
  • David E. Fractor, Chief Financial Officer (Age 55)
  • Rahul Singhvi, Lead Independent Director (Age 50)
  • John S. Yu M.D., Director (Age 51)
  • Anthony Gregg Lapointe CPA, Independent Director (Age 58)
  • Mark A. Schlossberg Esq., Independent Director (Age 56)
  • Gary S. Titus, Independent Director (Age 57)

How do I buy ImmunoCellular Therapeutics Ltd stock?

Shares of ImmunoCellular Therapeutics Ltd can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ImmunoCellular Therapeutics Ltd's stock price today?

One share of ImmunoCellular Therapeutics Ltd stock can currently be purchased for approximately $0.34.

How big of a company is ImmunoCellular Therapeutics Ltd?

ImmunoCellular Therapeutics Ltd has a market capitalization of $5.35 million.

How can I contact ImmunoCellular Therapeutics Ltd?

ImmunoCellular Therapeutics Ltd's mailing address is 30721 Russell Ranch Rd Ste 140, WESTLAKE VILLAGE, CA 91362-7383, United States. The biotechnology company can be reached via phone at +1-818-2642300.


MarketBeat Community Rating for ImmunoCellular Therapeutics Ltd (NYSEAMERICAN IMUC)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  112 (Vote Outperform)
Underperform Votes:  95 (Vote Underperform)
Total Votes:  207
MarketBeat's community ratings are surveys of what our community members think about ImmunoCellular Therapeutics Ltd and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 0 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Hold (Score: 2.00)
Analysts' Consensus Price Target: N/A

Consensus Price Target History for ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC)

Price Target History for ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC)

Analysts' Ratings History for ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC)

Show:
DateFirmActionRatingPrice TargetDetails
8/24/2017Maxim GroupReiterated RatingHoldView Rating Details
(Data available from 11/21/2015 forward)

Earnings

Earnings History and Estimates Chart for ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC)

Earnings by Quarter for ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC)

Earnings History by Quarter for ImmunoCellular Therapeutics Ltd (NYSEAMERICAN IMUC)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/10/2016Q316($0.04)($0.04)ViewN/AView Earnings Details
8/22/2016Q2($0.07)($0.06)ViewListenView Earnings Details
5/12/2016Q116($0.07)($0.06)ViewListenView Earnings Details
3/30/2016Q415($0.06)($0.05)ViewListenView Earnings Details
11/10/2015Q315($0.06)($0.04)ViewN/AView Earnings Details
8/6/2015Q215($0.05)($0.03)ViewN/AView Earnings Details
5/11/2015Q1($0.02)($0.02)ViewN/AView Earnings Details
3/9/2015Q414($0.05)($0.04)ViewN/AView Earnings Details
11/10/2014Q314($0.06)($0.03)ViewN/AView Earnings Details
8/11/2014($0.06)($0.04)ViewN/AView Earnings Details
5/9/2014Q114($0.04)($0.05)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.08)($0.05)ViewN/AView Earnings Details
3/5/2013Q4 2012($0.08)$0.01ViewN/AView Earnings Details
11/12/2012Q312($0.02)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for ImmunoCellular Therapeutics Ltd (NYSEAMERICAN IMUC)

Insider Trades by Quarter for ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC)

Insider Trades by Quarter for ImmunoCellular Therapeutics Ltd (NYSEAMERICAN IMUC)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/30/2015Andrew GengosCEOBuy10,000$0.44$4,400.00View SEC Filing  
2/18/2015Andrew GengosCEOBuy41,333$0.60$24,799.80View SEC Filing  
2/18/2015Andrew GengosCEOBuy41,333$0.60$24,799.80View SEC Filing  
2/18/2015Anthony GringeriVPBuy30,000$0.60$18,000.00View SEC Filing  
2/18/2015David FractorVPBuy16,667$0.60$10,000.20View SEC Filing  
8/21/2014Anthony GringeriVPBuy11,000$0.91$10,010.00View SEC Filing  
8/14/2014Andrew GengosCEOBuy10,000$0.90$9,000.00View SEC Filing  
12/20/2013Gary TitusDirectorBuy18,000$0.78$14,040.00View SEC Filing  
12/18/2013Andrew GengosCEOBuy27,000$0.72$19,440.00View SEC Filing  
10/21/2013John S YuInsiderSell267,387$2.91$778,096.17View SEC Filing  
8/29/2013James BenderVPSell14,203$2.87$40,762.61View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for ImmunoCellular Therapeutics Ltd (NYSEAMERICAN IMUC)

Source:

Social Media

Social activity is not available for this stock.

Financials

Chart

ImmunoCellular Therapeutics Ltd (NYSEAMERICAN IMUC) Chart for Tuesday, November, 21, 2017
Loading chart…

This page was last updated on 11/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.